Targeting folates by carboxypeptidase G2: Potential applications in anticancer therapy

Onkologie

Volumn 23, Issue 6, 2000, Pages 538-543

  Krackhardt, A ^a   Schwartz, S ^a   Thiel, E ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Antitumor activity; Carboxypeptidase G2; Folates; Methotrexate rescue

Indexed keywords

CARBOXYPEPTIDASE G2; CYTOTOXIC AGENT; FOLIC ACID DERIVATIVE; METHOTREXATE; PRODRUG; TRIMETREXATE;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; BIOTRANSFORMATION; CANCER CHEMOTHERAPY; DRUG INTOXICATION; DRUG MEGADOSE; DRUG TARGETING; DRUG TUMOR LEVEL; FOLATE METABOLISM; REVIEW;

EID: 0034502691     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055003     Document Type: Review

References (41)

1. Carboxypeptidase displaying differential velocity in hydrolysis of methotrexate, 5-methyl-tetrahydrofolic acid, and leucovorin
2. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue
3. Purification and properties of Carboxypeptidase G1
4. Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity
5. Treatment of central nervous system tumors with methotrexate
6. Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida
7. Crystal structure of Carboxypeptidase G2, a bacterial enzyme with applications in cancer therapy
8. Purification and properties of Carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method
9. High-dose methotrexate: A critical reappraisal
10. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity
11. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity
12. Antifolates
13. Concepts in use of high-dose methotrexate therapy
14. Methotrexate nephrotoxicity
15. Methotrexate-induced renal impairment: Clinical studies and rescue from systemic toxicity with high dose leucovorin and thymidine
16. Removal of methotrexate, leucovorin and their metabolites by combined hemodialysis and hemoperfusion
17. Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis
18. Cerebrospinal fluid exchange after intrathecal methotrexate overdose. A report of two cases
19. Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose
20. Treatment of massive intrathecal methotrexate overdose by ventriculolumbar perfusion
21. The acute management of intrathecal methotrexate overdose: Pharmacologic rationale and guidelines
22. Intrathecal leucovorin after intrathecal methotrexate overdose
23. Methotrexate pharmacokinetics following administration of recombinant Carboxypeptidase-G2 in rhesus monkeys
24. Rescue of experimental intrathecal methotrexate overdose with Carboxypeptidase G2
25. Carboxypeptidase G2 rescue after high-dose Methotrexate
26. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity
27. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction
28. Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2
29. Successful Carboxypeptidase G2 rescue in delayed Methotrexate elimination due to renal failure
30. Carboxypeptidase G2 rescue in a 79 year-old patient with cranial lymphoma after high-dose methotrexate induced acute renal failure
31. Antibody directed enzymes revive anti-cancer prodrugs concept
32. Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects
33. Anti-tumour effects of an antibody-Carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs
34. Novel prodrugs which are activated to cytotoxic alkylating agents by Carboxypeptidase G2
35. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethylbenzoyl compounds, products of prodrugs in antibody directed enzyme prodrug therapy (ADEPT)
36. ZD 2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts
37. Antibody-directed enzyme prodrug therapy: Pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial
38. Enhancement of Trimetrexate cytotoxicity in vitro and in vivo by Carboxypeptidase G2
39. Carboxypeptidase G2 and trimetrexate cause growth delay of human colonic cancer cells in vitro
40. Evaluation of clinical assays for measuring high-dose methotrexate in plasma
41. Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial